[The influence of chronic pentroxifylline medication on ergometric and hemodynamic parameters in intermittent claudication (author's transl)].
In an open clinical trial 14 patients with intermittent claudication caused by an obliteration of the femoral artery received 400 mg pentoxifylline 3 times daily over a period of 6 months. The walking distance, time to peak flow and calf ergometry showed a significant increase. Minor improvement of working hyperemia and peak flow could be found. The systolic pressure gradient over the obstruction didn't change. No patient complained about side effects.
D001157:Arterial Occlusive Diseases / Q000150:complications; D005081:Exercise Therapy; D005263:Femoral Artery; D006801:Humans; D006940:Hyperemia / Q000175:diagnosis; D007383:Intermittent Claudication / Q000188:drug therapy* / Q000209:etiology; D010431:Pentoxifylline / Q000627:therapeutic use*; D013805:Theobromine / Q000031:analogs & derivatives*
D013805:Theobromine; D010431:Pentoxifylline
Behandlung von Patienten mit arterieller Verschlusskrankheit (Stadium II) mit Pentoxifyllin. Hämodynamische und ergometrische Befunde.